Swiss Re Ltd / CH0126881561

Covid-19 may lead to longest period of peacetime excess mortality, says new Swiss Re report

Swiss Re Ltd / Key word(s): Research Update


16.09.2024 / 10:00 CET/CEST

---

Report suggests potential excess mortality in the general population of up to 3% for the US by 2033 and 2.5% in the UK, the longest period of elevated peacetime excess mortality in the US Key driver of excess mortality is the lingering impact of COVID-19; both as a direct cause of death, and as a contributor to cardiovascular mortality Reducing the impact of COVID-19 on elderly and vulnerable populations will be key to excess mortality returning to zero Zurich, 16 September 2024 – Four years after the peak of the COVID-19 pandemic, many countries are still reporting elevated all-cause excess mortality compared with pre-pandemic levels. According to Swiss Re Institute's report The future of excess mortality after COVID-19, if the ongoing impact of the disease is not curtailed, excess mortality rates in the general population may remain up to 3% higher than pre-pandemic levels in the US and 2.5% in the UK by 2033. Paul Murray, CEO L&H Reinsurance at Swiss Re says: "COVID-19 is far from over. The US reported an average of 1500 COVID-19 deaths a week for 2023 – comparable to fentanyl or firearm deaths.[1] If this continues, our analysis suggests a potential scenario of elevated excess mortality extending over the next decade. However, excess mortality can return to pre-pandemic levels much sooner. The first step is to get COVID under control, with measures such as vaccinations for the vulnerable. Over the longer term, medical advancements, a return to regular healthcare services, and the adoption of healthier lifestyle choices will be key." Excess mortality is a measure of the number of deaths above an expected level in a given population. Typically, all-cause excess mortality should be around zero, as the major causes of death remain relatively stable over the long-term baseline assumption. Fluctuations in excess mortality tend to be short-term, reflecting developments such as a large-scale medical breakthrough or the negative impact of a large epidemic. However, as society absorbs these events, excess mortality should revert to the baseline. With COVID-19 this has not been the case and all-cause excess mortality is still above the pre-pandemic baseline. In 2021, excess mortality spiked to 23% above the 2019 baseline in the US, and 11% in the UK[2]. As Swiss Re Institute's report estimates, in 2023, it remained significantly elevated in the range of 3–7% for the US, and 5–8% for the UK. If the underlying drivers of current excess mortality continue, Swiss Re Institute's analysis estimates that excess mortality may remain as high as 3% for the US and 2.5% for the UK by 2033. The primary driving factor of both current and future excess mortality is respiratory disease (including COVID-19 and influenza), with other causes including cardiovascular disease, cancer and metabolic illnesses. The cause of death split varies by a country's reporting mechanism. Optimistic scenarios require healthcare and medical advancements Swiss Re's report examines an optimistic scenario where excess mortality rates return to pre-pandemic levels as early as 2028. In this scenario, medical advances, such as weight loss injectables and cancer developments such as personalised mRNA vaccines, combine with a drop in the impact of COVID-19 and healthier lifestyle choices. Indirect impact of cardiovascular disease (CVD) mortality The interplay between COVID-19 and cardiovascular death rates is significant for excess mortality. The virus itself has a direct impact because it contributes to causes of death such as heart failure. Further, COVID-19 has had an indirect impact via the disruption to healthcare systems – a factor which emerged in the pandemic years. This disruption has led to a backlog of essential cardiac tests and surgeries, meaning that conditions such as hypertension have been underdiagnosed and therefore not treated. Implications for insurers Excess mortality in the general population is an important indicator for insurers, as shifts in the major causes of death may require a reassessment of additional risk in their mortality portfolios. The current levels of excess mortality are of concern. However, there are a range of tools available for insurers and reinsurers to manage this trend. Specific actions include adapting the underwriting philosophy, risk appetite, and mortality assumptions in pricing and reserving. Insurers can be proactive in targeting prevention programmes for policyholders, helping them in the joint effort to support longer, healthier lives.  

How to order this study: The future of excess mortality after COVID-19 is available in electronic format from Swissre.com.   

---

[1] US Centers for Disease Control and Prevention (CDC) data: In 2021, during the peak of the pandemic, COVID-19 claimed 9 037 lives a week, this dropped to 1 453 average weekly deaths in 2023. In comparison, in 2023, synthetic opioids (fentanyl) claimed 1 437 average weekly deaths, and firearms resulted in 900 average weekly deaths.

[2] Human Mortality Database provides data on actual mortality rate, while Swiss Re Institute analysis forms baseline calculations  

For further information please contact Swiss Re Media Relations: + 41 (0)43 285 7171 or [e-mail].
Please use this link to access Swiss Re's press releases.

Swiss Re
The Swiss Re Group is one of the world’s leading providers of reinsurance, insurance and other forms of insurance-based risk transfer, working to make the world more resilient. It anticipates and manages risk – from natural catastrophes to climate change, from ageing populations to cyber crime. The aim of the Swiss Re Group is to enable society to thrive and progress, creating new opportunities and solutions for its clients. Headquartered in Zurich, Switzerland, where it was founded in 1863, the Swiss Re Group operates through a network of around 80 offices globally. Cautionary note on forward-looking statements
Certain statements and illustrations contained herein are forward-looking. These statements (including as to plans, objectives, targets, and trends) and illustrations provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical fact or current fact. Further information on forward looking statements can be found in the Legal Notice section of Swiss Re's website.

---

End of Media Release

---

Language:	English
Company:	Swiss Re Ltd
	Mythenquai 50/60
	8022 Zurich
	Switzerland
Phone:	[phone]
E-mail:	[e-mail]
Internet:	www.swissre.com
ISIN:	CH0126881561
Valor:	12688156
Listed:	SIX Swiss Exchange
EQS News ID:	1988817

End of News	EQS News Service

---

1988817  16.09.2024 CET/CEST